AUROBINDO PHARMA Results Analysis-Q2FY2027
AUROPHARMA Financial performance and key operating metrics (Consolidated) : Operating Revenue for Q2FY27 is Rs. 10,263 Crs., 24.6% growth YoY, Total Income is Rs. 10,432 Crs., 24.09% growth YoY, Gross Profit Rs. 6,280 Crs., 28.21% growth YoY, EBITDA is Rs. 2,156 Crs., 32.31% growth YoY, EBITDA Margin is 21% improved by 122 Basis points YoY, PBT Rs. 1,688 Crs. 32.27% growth YoY, PAT Rs. 1,124 Crs. 32.5% growth YoY. On QoQ basis Op. Revenue is up by 12.7%, Total Income is up by 10.8%, EBITDA is up by 17.38%, PBT is up by 11.39% PAT is also up by 8.9%. highest ever revenue for the quarter,” attributed to core-market performance, integration benefits, and progress on strategic priorities. Formulations: INR 9,102 crore (+24% YoY) = 89% of revenue. API: INR 1,162 crore (+21% YoY) = 11%; positioned as both a profit center and an integration/supply-security lever. United States (Formulations + specialties) :Revenue: INR 4,555 crore / USD 477m (+25% YoY). Europe (Formulations + biosimilars early ramp) : Revenue: EUR 288m, +18% constant currency; sustained strong execution.



















